

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	Apolipoprotein C-III (APOCIII; APOC3)	Rat studies suggest inhibiting APOC3 could help treat type 1 diabetes. In diabetes-prone rats, serum levels of Apoc3 were higher than those in normal controls. In the same rats, an <i>Apoc3</i> antisense oligonucleotide increased the time to onset of diabetes compared with an inactive control antisense oligonucleotide. Future studies could include testing differing dose regimens of the <i>APOC3</i> antisense oligonucleotide. ISIS-APOCIII, an antisense inhibitor of APOC3 from Isis Pharmaceuticals Inc., is in Phase I testing to treat hypertriglyceridemia.	Patent and licensing status unavailable	Holmberg, R. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online June 13, 2011; doi:10.1073/pnas.1019553108 Contact: Lisa Juntti-Berggren, Karolinska Institute, Stockholm, Sweden e-mail: lisa.juntti-berggren@ki.se
<p>SciBX 4(26); doi:10.1038/scibx.2011.738 Published online June 30, 2011</p>				